← Back to Search

Monoclonal Antibodies

177Lu-DTPA-omburtamab for Leptomeningeal Metastasis

Phase 1 & 2
Waitlist Available
Research Sponsored by Y-mAbs Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Primary ductal or lobular breast cancer, non-small cell lung cancer, or malignant melanoma
Type I or Type II LM with a "confirmed" or "probable" diagnosis according to EANO-ESMO guidelines 2017
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial will test a new treatment for adults with cancer that has spread to the meninges (the thin layer of tissue that covers the brain and spinal cord). The treatment is a radioactive antibody that targets a protein called B7-H3.

Eligible Conditions
  • Leptomeningeal Metastasis
  • Solid Tumors

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of AEs and SAEs
Incidence of adverse events (AEs) and serious adverse events (SAEs)
Secondary outcome measures
Absorbed radiation dose of lutetium-177 in blood and cerebrospinal fluid (CSF)
Dosimetry analysis of lutetium-177
Elimination Half Life in CSF
+9 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: 177Lu-DTPA-omburtamabExperimental Treatment1 Intervention
Intracerebroventricular administration of 177Lu-DTPA-omburtamab for up to five cycles.

Find a Location

Who is running the clinical trial?

Y-mAbs TherapeuticsLead Sponsor
25 Previous Clinical Trials
1,557 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)
2022. "177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04315246.
~0 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top